Abstract 1488P
Background
Platinum-based chemotherapy (CT) with PDL-1 blockade is the standard of care in ES-SCLC. Relevant randomized controlled trials were restricted to patients(pts) with ECOG PS 0-1 at initiation of therapy. These trials also prohibited use of consolidation radiotherapy (RT) or salvage RT to treat of oligo-progression. We aimed to evaluate outcomes in pts with poor ECOG PS and those receiving non-palliative RT, as well as the prevalence and outcomes of durvalumab (DRV) beyond progression.
Methods
A retrospective data collection including pts from 11 centers in four countries. Primary endpoints were overall survival (OS) and duration of treatment (DOT) in the overall population and in the subgroup of pts with ECOG ≥2. Secondary endpoints included safety, OS and DOT in pts treated with non-palliative RT as well as the use of ICI beyond progression.
Results
A total of 100 pts received durvalumab with CT for ES-SCLC. 68% were male, median age was 65 years (range 39-83) and 23% had an ECOG ≥2. Overall, 29% of patients received RT during durvalumab treatment, 22% as salvage/consolidation. Fifteen pts (15%) were treated with DRV beyond progression for a median of 4 cycles (range 1-14). Median OS in the entire cohort was 11.5mo, 13.3mo in pts with ECOG 0-1 and 10.3mo in pts with ECOG ≥2 (p=0.028). Median DOT in the entire cohort was 4.5mo and 4.2 in pts with ECOG ≥2 (p=0.006). Pts receiving non-palliative RT showed a trend toward improved OS and DOT (Table). Eight pts (8%) discontinued DRV due to immune-related adverse events. Table: 1488P
mDOT and mOS in pts receiving non-palliative RT
All patients | Pts with consolidation/salvage RT | P-VALUE | |
mDOT with durvalumab (months) | 4.5 | 5.9 | 0.056 |
mOS (months) | 11.5 | 14.7 | 0.190 |
Conclusions
Treatment with CT and DRV is safe and effective in pts with ES-SCLC with ECOG PS ≥2 as well as in pts receiving concomitant radiotherapy. Treatment discontinuation rate due to toxicity was comparable to that reported in the CASPIAN study.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1564P - Gut microbiome and metabolome are associated with the response to chemoradiotherapy in patients with esophageal cancer
Presenter: Mingqiang Lin
Session: Poster session 21
1565P - ERCC1 gene polymorphism influences overall survival in early oesophageal cancer: Results from the phase III MRC OEO2 randomised controlled trial
Presenter: Georgina Keogh
Session: Poster session 21
1566P - Clinical relevance of circulating tumor DNA in HER2 -positive advanced gastric cancer: Results from phase Ib trial of HER2 and PD-1 dual targeted therapy (Ni-High)
Presenter: Hiroki Osumi
Session: Poster session 21
1567P - The effect of SGLT2i and DPP4i on new-onset gastric cancer and gastric diseases in type 2 diabetes mellitus: A population-based cohort study
Presenter: Hou In Chou
Session: Poster session 21
1568P - Establishment of a platform to predict radiation sensitivity in organoids derived from esophageal cancer patients
Presenter: Ga Yeon Kim
Session: Poster session 21